Thus, RARβ may exert an effect on NAFLD progression via its actions in the intestine, and RARβ and its signaling pathway in the gut could be novel targets for NAFLD therapy development. The gene discussed is RARB; the disease is metabolic dysfunction-associated steatotic liver disease.